Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP in Relapsed Favorable-Prognosis NSGCT
NCT00127049Phase 2Unknown
- Sponsor
- Gustave Roussy
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in non-seminomatous germ cell tumor (NSGCT), sponsored by Gustave Roussy. Primary endpoint: Complete Response Rate. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT00127049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127049.